Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Director | May 06, 2019 | May 08, 2019 |
| CHURCH & DWIGHT CO INC /DE/CHD · Entity 2509 | Director | July 01, 2026 | July 02, 2026 |
| DENTSPLY SIRONA Inc.XRAY · Entity 4448 | Director | June 03, 2026 | June 05, 2026 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director | June 05, 2025 | June 09, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date May 06, 2019 · Filed May 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 18,257 |
Reported balance
After 2019-05-08 transaction · row 1
1 source rowRow 1 · 2019-05-08 · Exercise / conversion · Acquired 6,107 · Balance 18,257 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.05 · Expires 2029-05-06 | Direct | 28,044 |
Reported balance
After 2019-05-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-06 · Grant · Acquired 28,044 · Balance 28,044 F2: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,459 |
Reported balance
After 2019-05-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-06 · Grant · Acquired 6,459 · Balance 6,459 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-05-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-05-08 · Exercise / conversion · Disposed 6,107 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
F3: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date.
F4: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019.
CHURCH & DWIGHT CO INC /DE/
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,188 |
Reported balance
After 2026-07-01 transaction · row 1
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 736 · Balance 21,188 |
DENTSPLY SIRONA Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,324 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 22,822 · Balance 67,324 F1: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date June 05, 2025 · Filed June 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 73,697 |
Reported balance
After 2025-06-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-06 · Exercise / conversion · Acquired 9,632 · Balance 73,697 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-06-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-06 · Exercise / conversion · Disposed 9,632 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 14,492 |
Reported balance
After 2025-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-06-05 · Grant · Acquired 14,492 · Balance 14,492 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025.
F4: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Impax Laboratories, LLC
Report date May 04, 2018 · Filed May 08, 2018
Section 16 reporting ended · disclosed 2018-05-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 1
1 source rowRow 1 · 2018-05-04 · Disposition to issuer · Disposed 6,642 · Balance 0 F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). |
| Restricted Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 2
1 source rowRow 2 · 2018-05-04 · Disposition to issuer · Disposed 5,508 · Balance 0 F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.40 · Expires 2027-05-16 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-04 · Disposition to issuer · Disposed 10,575 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.33 · Expires 2026-05-17 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-04 · Disposition to issuer · Disposed 10,575 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.42 · Expires 2025-10-07 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-04 · Disposition to issuer · Disposed 8,100 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock").
F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock.
F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 2, 2026 22:30 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantCommon Stock | 736 | $96.88 | $71,303.68 |
DisclosureSEC source: 0001012975-26-000614 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,188 Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 21:37 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 22,822 | $0.00 | $0.00 |
DisclosureSEC source: 0000818479-26-000191 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,324 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| May 04, 2026 Filed May 6, 2026 14:44 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantStock Option (right to buy) · Derivative | 3,060 | $0.00 Strike: $92.89 | $0.00 |
DisclosureSEC source: 0000313927-26-000239 · form4.xml · derivative · entry 6 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,060 Underlying: Common Stock · 3,060 shares Expires 2036-05-04 Read SEC document |
| May 04, 2026 Filed May 6, 2026 14:44 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantCommon Stock | 920 | $0.00 | $0.00 |
DisclosureSEC source: 0000313927-26-000239 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 920 F1 · date: Represents restricted stock units (RSUs) granted on May 4, 2026. The RSUs will vest, subject to certain conditions, in full on the first anniversary of the grant date. Each RSU represents the contingent right to receive one share of common stock of the Issuer upon vesting. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 17:24 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | Exercise / conversionStock Option (right to buy) · Derivative | 12,960 | $0.00 Strike: $49.62 | $0.00 |
DisclosureSEC source: 0000313927-26-000050 · form4.xml · derivative · entry 6 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,960 shares Expires 2026-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 17:24 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | SaleCommon Stock | 12,960 | $101.00 | $1,308,960.00 |
DisclosureSEC source: 0000313927-26-000050 · form4.xml · nonDerivative · entry 2 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,102 Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 17:24 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | Exercise / conversionCommon Stock | 12,960 | $49.62 | $643,075.20 |
DisclosureSEC source: 0000313927-26-000050 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:39 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 200.899 | $0.00 | $0.00 |
DisclosureSEC source: 0000818479-26-000038 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,501.066 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| October 10, 2025 Filed Oct 15, 2025 21:00 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 179.449 | $0.00 | $0.00 |
DisclosureSEC source: 0000818479-25-000219 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,300.167 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 20:49 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 139.41 | $0.00 | $0.00 |
DisclosureSEC source: 0000818479-25-000131 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,120.718 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| June 30, 2025 Filed Jul 8, 2025 14:38 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantCommon Stock | 729 | $96.11 | $70,064.19 |
DisclosureSEC source: 0001127602-25-019009 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,102 Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 20:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 9,632 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083777 · ownership.xml · derivative · entry 2 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025. F3 · derivative.expiration_date: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 20:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 9,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-083777 · ownership.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 14,492 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083777 · ownership.xml · derivative · entry 3 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,492 Underlying: Ordinary Shares · 14,492 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F4 · derivative.expiration_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:26 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 13,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015717 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,981.308 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| May 02, 2025 Filed May 6, 2025 14:45 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantStock Option (right to buy) · Derivative | 2,890 | $0.00 Strike: $92.94 | $0.00 |
DisclosureSEC source: 0001127602-25-013419 · form4.xml · derivative · entry 5 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,890 Underlying: Common Stock · 2,890 shares Expires 2035-05-02 Read SEC document |
| May 02, 2025 Filed May 6, 2025 14:45 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantCommon Stock | 860 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013419 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 860 F1 · date: Represents restricted stock units (RSUs) granted on May 2, 2025. The RSUs will vest, subject to certain conditions, in full on the first anniversary of the grant date. Each RSU represents the contingent right to receive one share of common stock of the Issuer upon vesting. Read SEC document |
| April 11, 2025 Filed Apr 15, 2025 20:29 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 87.462 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-012081 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,101.308 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 22:48 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 68.367 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-001227 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,013.846 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 21:10 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 47.588 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-025518 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,945.479 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| July 12, 2024 Filed Jul 15, 2024 21:10 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 51.346 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-020401 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,897.891 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 15:48 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantCommon Stock | 676 | $103.68 | $70,087.68 |
DisclosureSEC source: 0001127602-24-019682 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,373 Read SEC document |
| June 15, 2024 Filed Jun 17, 2024 11:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 21,108 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074012 · ownership.xml · derivative · entry 2 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,108 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted Share Units were granted on June 15, 2023 and vested on June 15, 2024. F3 · derivative.expiration_date: Restricted Share Units were granted on June 15, 2023 and vested on June 15, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 15, 2024 Filed Jun 17, 2024 11:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 21,108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-074012 · ownership.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 11:36 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 9,632 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071066 · ownership.xml · derivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,632 Underlying: Ordinary Shares · 9,632 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 6, 2024 and vest on June 6, 2025. F2 · derivative.expiration_date: Restricted share units were granted on June 6, 2024 and vest on June 6, 2025. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:32 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 7,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016580 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,846.545 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| May 03, 2024 Filed May 6, 2024 16:54 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantStock Option (right to buy) · Derivative | 2,360 | $0.00 Strike: $106.11 | $0.00 |
DisclosureSEC source: 0001127602-24-014233 · form4.xml · derivative · entry 4 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,360 Underlying: Common Stock · 2,360 shares Expires 2034-05-03 Read SEC document |
| May 03, 2024 Filed May 6, 2024 16:54 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014233 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750 F1 · shares: Represents restricted stock units (RSUs) granted on May 3, 2024. The RSUs will vest, subject to certain conditions, in full on the first anniversary of the grant date. Each RSU represents the contingent right to receive one share of common stock of the Issuer upon vesting. Read SEC document |
| April 12, 2024 Filed Apr 15, 2024 23:38 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 26.426 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012909 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,852.545 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| January 12, 2024 Filed Jan 16, 2024 19:14 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 21.479 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-001319 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,826.119 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| October 13, 2023 Filed Oct 16, 2023 21:23 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 48.731 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-025919 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,804.64 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 20:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 15,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-044791 · doc4.xml · derivative · entry 2 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,810 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on August 4, 2022 and vested on August 4, 2023. F3 · derivative.expiration_date: Restricted share units were granted on August 4, 2022 and vested on August 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 20:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-044791 · doc4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 21:23 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 41.45 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020841 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,755.909 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 16:04 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantCommon Stock | 699 | $100.23 | $70,060.77 |
DisclosureSEC source: 0001127602-23-019689 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,697 Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 11:38 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 21,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038224 · doc4.xml · derivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,108 Underlying: Ordinary Shares · 21,108 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 15, 2023 and vest on June 15, 2024. F2 · derivative.expiration_date: Restricted share units were granted on June 15, 2023 and vest on June 15, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 25, 2023 Filed May 26, 2023 21:01 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 5,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016980 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,714.459 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| April 28, 2023 Filed May 1, 2023 16:48 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantStock Option (right to buy) · Derivative | 2,880 | $0.00 Strike: $97.12 | $0.00 |
DisclosureSEC source: 0001127602-23-013878 · form4.xml · derivative · entry 3 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,880 Underlying: Common Stock · 2,880 shares Expires 2033-04-28 Read SEC document |
| April 28, 2023 Filed May 1, 2023 16:48 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantCommon Stock | 820 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-013878 · form4.xml · nonDerivative · entry 2 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 820 F1 · shares: Represents restricted stock units (RSUs) granted on April 28, 2023. The RSUs will vest, subject to certain conditions, in full on the first anniversary of the grant date. Each RSU represents the contingent right to receive one share of common stock of the Issuer upon vesting. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 21:14 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 22.836 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-013154 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,295.459 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| January 13, 2023 Filed Jan 13, 2023 22:05 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 25.055 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-001417 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,272.623 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:42 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 6,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025783 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,247.568 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 11:27 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 15,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-044699 · doc4.xml · derivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,810 Underlying: Ordinary Shares · 15,810 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on August 4, 2022 and vest on August 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on August 4, 2022 and vest on August 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 14:50 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantCommon Stock | 648 | $92.66 | $60,043.68 |
DisclosureSEC source: 0001127602-22-018370 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,998 Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 11:44 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 14,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037253 · doc4.xml · derivative · entry 2 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,479 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 14, 2021 and vested on June 14, 2022. F3 · derivative.expiration_date: Restricted share units were granted on June 14, 2021 and vested on June 14, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 11:44 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 14,479 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-037253 · doc4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 13, 2022 Filed Jun 14, 2022 17:39 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantStock Option · Derivative | 6,400 | $0.00 Strike: $84.85 | $0.00 |
DisclosureSEC source: 0001127602-22-017374 · form4.xml · derivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,400 Underlying: Common Stock · 6,400 shares Expires 2032-06-13 Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 22:11 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 7.609 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-011856 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,865.568 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| January 14, 2022 Filed Jan 20, 2022 00:22 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 5.952 | $0.00 | $0.00 |
DisclosureSEC source: 0001306483-22-000005 · primary_doc.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,857.959 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 21:06 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 5.523 | $60.01 | $331.44 |
DisclosureSEC source: 0001127602-21-026977 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,852.007 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.